Effect of Levosimendan Use on All-Cause Mortality in Out-of-Hospital Cardiac Arrest Survivors After Extracorporeal Cardiopulmonary Resuscitation

<b>Background:</b> Survivors of out-of-hospital cardiac arrest (OHCA) after external cardiopulmonary resuscitation (ECPR) have a mortality rate as high as 50–70%. The use of vasoactive inotropes worsen the mortality rate at admission. The administration of levosimendan within 72 h of ECP...

Full description

Saved in:
Bibliographic Details
Main Authors: Da-Long Chen, Yu-Kai Lin, Guei-Jane Wang, Kuan-Cheng Chang
Format: Article
Language:English
Published: MDPI AG 2025-04-01
Series:Biomedicines
Subjects:
Online Access:https://www.mdpi.com/2227-9059/13/4/955
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850183744517832704
author Da-Long Chen
Yu-Kai Lin
Guei-Jane Wang
Kuan-Cheng Chang
author_facet Da-Long Chen
Yu-Kai Lin
Guei-Jane Wang
Kuan-Cheng Chang
author_sort Da-Long Chen
collection DOAJ
description <b>Background:</b> Survivors of out-of-hospital cardiac arrest (OHCA) after external cardiopulmonary resuscitation (ECPR) have a mortality rate as high as 50–70%. The use of vasoactive inotropes worsen the mortality rate at admission. The administration of levosimendan within 72 h of ECPR facilitates extracorporeal membrane oxygenation (ECMO) weaning, so it is important to determine whether levosimendan improves mortality. <b>Methods:</b> This retrospective cohort study included 158 patients with OHCA of cardiac origin who had undergone ECPR and were hospitalized between January 2015 and December 2024. This study was conducted in the intensive care unit of China Medical University Hospital, Taichung, Taiwan. Twenty-three patients received levosimendan within 72 h, whereas the others did not receive levosimendan. Primary endpoints included ECMO weaning failure rate and 90-day all-cause mortality rate. Kaplan–Meier survival curve analysis was also performed. Covariates for all-cause mortality were estimated and adjusted by using Cox regression modeling. <b>Results:</b> The levosimendan group exhibited lower rates of ECMO weaning failure and 90-day all-cause mortality than the control group (13.0% vs. 52.6% and 17.4% vs. 57.0%, respectively; both <i>p</i> < 0.001). The 90-day survival curve analysis revealed that the levosimendan and control groups had survival rates of 82.6% and 43.0%, respectively (log-rank <i>p</i> < 0.001). Administration of levosimendan within 72 h resulted in a odds ratio of 0.36 (95% confidence interval: 0.18−0.79, <i>p</i> = 0.01). <b>Conclusions:</b> Administering levosimendan within 72 h of ECPR could be a protective factor in improving all-cause mortality.
format Article
id doaj-art-dcf31e6d046d4ec5a903ada5ded5dc3c
institution OA Journals
issn 2227-9059
language English
publishDate 2025-04-01
publisher MDPI AG
record_format Article
series Biomedicines
spelling doaj-art-dcf31e6d046d4ec5a903ada5ded5dc3c2025-08-20T02:17:14ZengMDPI AGBiomedicines2227-90592025-04-0113495510.3390/biomedicines13040955Effect of Levosimendan Use on All-Cause Mortality in Out-of-Hospital Cardiac Arrest Survivors After Extracorporeal Cardiopulmonary ResuscitationDa-Long Chen0Yu-Kai Lin1Guei-Jane Wang2Kuan-Cheng Chang3Graduate Institute of Clinical Medical Science, China Medical University, Taichung 40402, TaiwanDivision of Cardiovascular Medicine, Department of Medicine, China Medical University Hospital, Taichung 40447, TaiwanGraduate Institute of Clinical Medical Science, China Medical University, Taichung 40402, TaiwanGraduate Institute of Clinical Medical Science, China Medical University, Taichung 40402, Taiwan<b>Background:</b> Survivors of out-of-hospital cardiac arrest (OHCA) after external cardiopulmonary resuscitation (ECPR) have a mortality rate as high as 50–70%. The use of vasoactive inotropes worsen the mortality rate at admission. The administration of levosimendan within 72 h of ECPR facilitates extracorporeal membrane oxygenation (ECMO) weaning, so it is important to determine whether levosimendan improves mortality. <b>Methods:</b> This retrospective cohort study included 158 patients with OHCA of cardiac origin who had undergone ECPR and were hospitalized between January 2015 and December 2024. This study was conducted in the intensive care unit of China Medical University Hospital, Taichung, Taiwan. Twenty-three patients received levosimendan within 72 h, whereas the others did not receive levosimendan. Primary endpoints included ECMO weaning failure rate and 90-day all-cause mortality rate. Kaplan–Meier survival curve analysis was also performed. Covariates for all-cause mortality were estimated and adjusted by using Cox regression modeling. <b>Results:</b> The levosimendan group exhibited lower rates of ECMO weaning failure and 90-day all-cause mortality than the control group (13.0% vs. 52.6% and 17.4% vs. 57.0%, respectively; both <i>p</i> < 0.001). The 90-day survival curve analysis revealed that the levosimendan and control groups had survival rates of 82.6% and 43.0%, respectively (log-rank <i>p</i> < 0.001). Administration of levosimendan within 72 h resulted in a odds ratio of 0.36 (95% confidence interval: 0.18−0.79, <i>p</i> = 0.01). <b>Conclusions:</b> Administering levosimendan within 72 h of ECPR could be a protective factor in improving all-cause mortality.https://www.mdpi.com/2227-9059/13/4/955out-of-hospital cardiac arrestextracorporeal cardiopulmonary resuscitationlevosimendan inodilatorextracorporeal membrane oxygenation
spellingShingle Da-Long Chen
Yu-Kai Lin
Guei-Jane Wang
Kuan-Cheng Chang
Effect of Levosimendan Use on All-Cause Mortality in Out-of-Hospital Cardiac Arrest Survivors After Extracorporeal Cardiopulmonary Resuscitation
Biomedicines
out-of-hospital cardiac arrest
extracorporeal cardiopulmonary resuscitation
levosimendan inodilator
extracorporeal membrane oxygenation
title Effect of Levosimendan Use on All-Cause Mortality in Out-of-Hospital Cardiac Arrest Survivors After Extracorporeal Cardiopulmonary Resuscitation
title_full Effect of Levosimendan Use on All-Cause Mortality in Out-of-Hospital Cardiac Arrest Survivors After Extracorporeal Cardiopulmonary Resuscitation
title_fullStr Effect of Levosimendan Use on All-Cause Mortality in Out-of-Hospital Cardiac Arrest Survivors After Extracorporeal Cardiopulmonary Resuscitation
title_full_unstemmed Effect of Levosimendan Use on All-Cause Mortality in Out-of-Hospital Cardiac Arrest Survivors After Extracorporeal Cardiopulmonary Resuscitation
title_short Effect of Levosimendan Use on All-Cause Mortality in Out-of-Hospital Cardiac Arrest Survivors After Extracorporeal Cardiopulmonary Resuscitation
title_sort effect of levosimendan use on all cause mortality in out of hospital cardiac arrest survivors after extracorporeal cardiopulmonary resuscitation
topic out-of-hospital cardiac arrest
extracorporeal cardiopulmonary resuscitation
levosimendan inodilator
extracorporeal membrane oxygenation
url https://www.mdpi.com/2227-9059/13/4/955
work_keys_str_mv AT dalongchen effectoflevosimendanuseonallcausemortalityinoutofhospitalcardiacarrestsurvivorsafterextracorporealcardiopulmonaryresuscitation
AT yukailin effectoflevosimendanuseonallcausemortalityinoutofhospitalcardiacarrestsurvivorsafterextracorporealcardiopulmonaryresuscitation
AT gueijanewang effectoflevosimendanuseonallcausemortalityinoutofhospitalcardiacarrestsurvivorsafterextracorporealcardiopulmonaryresuscitation
AT kuanchengchang effectoflevosimendanuseonallcausemortalityinoutofhospitalcardiacarrestsurvivorsafterextracorporealcardiopulmonaryresuscitation